CORE--TISSUE CULTURE AND MONOCLONAL ANTIBODY

核心——组织培养和单克隆抗体

• 批准号: 6589974
• 负责人: Dean P Edwards
• 金额: $ 25.04万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-06 至 2003-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6589974
• 关键词: Baculoviridae; antitumor antibody; biomedical facility; hybridomas; monoclonal antibody; tissue /cell culture

Description: (Applicant's Description) The Tissue Culture/Monoclonal Antibody Core (TC/MB) has served for the past 12 years as an efficient resource for UCCC investigators to access specialized cell culture technologies and produce monoclonal antibodies (MAbs). Cell fusion and construction of MAb secreting hybridoma cell lines has been offered since the founding of the facility and continues to be a major function. Production of MAbs from large scale growth of hybridomas in conventional spinner vessels and in hollow-fiber bioreactors was established more recently and this component of hybridoma services has grown by approximately 300% over the past four years. Construction of baculovirus vectors and expression of recombinant proteins in insect cells, established as a service at the last review, has also grown significantly (200-300%) to become a major function of the Core. The TC/MB Core has developed and maintains a repository of more than 150 cancer cell lines in liquid nitrogen and provides UCCC investigators with seed cultures for experiments or cell pellets from large volume cultures as a source for isolation of macromolecules or other cellular factors. In 1997, an On-Site Media Supply Center was established that provides commercially prepared liquid growth medium, supplements and serum at substantially reduced prices and has saved UCCC investigators over $180,000. In addition to technical services, the TC/MB core provides consultation/training and quality control procedures. One or more of the TC/MB Core services has been used by 117 UCCC investigators since the last review of the TC/MB. The users are from 9 of 10 Programs and more than 95% hold peer-reviewed extramural research grants. The custom technological services have provided support for more than 180 publications of UCCC investigators over the last 4 years. The future goal of the TC/MB Core is to continue to provide existing quality services and expand the capacity of custom baculovirus services and large scale growth of hybridomas that have increased the most. To expand the capacity of these services, a small annual increase of 5.5% in Core grant budget is requested so that the technical staff can increase from 3 to 4 individuals. Additionally, new equipment is requested in the second year.

描述：（申请人的描述）组织培养/单克隆 抗体核心（TC/MB）在过去的12年中一直担任高效 UCCC调查人员访问专业细胞培养的资源 技术并产生单克隆抗体（mAb）。细胞融合和 自从以来，已经提供了MAB分泌杂交瘤细胞系的构建 该设施的建立并继续是主要功能。生产 传统旋转器容器中杂交大瘤的大规模生长的mAb和 在空心纤维生物反应器中，最近建立了该组件 在过去的四个中，杂交瘤服务的增长约为300％ 年。杆状病毒载体的构建和重组的表达 昆虫细胞中的蛋白质是在上次评论中作为服务的，具有 也显着增长（200-300％），成为核心的主要功能。 TC/MB核心已经开发并维护了150多个存储库 液氮中的癌细胞系，为UCCC研究者提供种子 来自大容量培养的实验或细胞颗粒的培养物作为一种 分离大分子或其他细胞因子的来源。 1997年， 建立了现场媒体供应中心，可在商业上提供 准备的液体生长培养基，补充剂和血清大大降低 价格并为UCCC调查人员节省了超过18万美元。此外 技术服务，TC/MB核心提供咨询/培训和质量 控制程序。一种或多种TC/MB核心服务已被使用 自上次审查TC/MB以来，117 UCCC调查人员。用户来自 10个计划中的9个和95％以上的计划进行了同行评审的校外研究 赠款。自定义技术服务为超过的支持提供了支持 在过去的四年中，UCCC调查人员的180名出版物。未来的目标 TC/MB核心的核心是继续提供现有的质量服务和 扩大自定义杆状病毒服务的能力和大规模增长 增加最大的杂交瘤。扩大这些能力 服务，要求核心赠款预算的每年增加5.5％，因此 技术人员可以从3个人增加到4个人。此外， 第二年要求新设备。